Lesion tissue microenvironment (LME)

The lesion tissue microenvironment (LME) refers to the complex, multi-component ecosystem that surrounds and interacts with pathological cells in diseases such as cancer, multiple sclerosis, and atherosclerosis (Source: NIH, 2023). It comprises a diverse array of cellular elements, including infiltrating immune cells, activated fibroblasts, and vascular endothelial cells, as well as non-cellular components like the extracellular matrix (ECM) and a milieu of signaling molecules such as cytokines and growth factors (Source: PubMed, 2021). Rather than being a passive background, the LME actively influences disease progression, often by creating an immunosuppressive or pro-survival niche that protects the lesion from the host's immune system and medical interventions (Source: Nature Reviews, 2020). In oncology, the tumor microenvironment (TME) is a well-studied subset of the LME that promotes angiogenesis and metastasis while hindering T-cell activity. Therapeutic targeting of the LME involves strategies such as neutralizing pro-angiogenic factors, blocking immune checkpoints, or remodeling the ECM to improve drug delivery and immune access (Source: StatPearls, 2023). Understanding the spatial and temporal dynamics of the LME is crucial for developing precision medicines that can effectively penetrate and alter these pathological niches.

Other names

Tissue microenvironmentLocal microenvironmentPathological nicheTumor microenvironmentInflammatory microenvironment

Drugs targeting the lesion microenvironment function by altering the local signaling milieu, such as neutralizing growth factors (e.g., VEGF), blocking immune checkpoints (e.g., PD-1/PD-L1), or inhibiting matrix-remodeling enzymes to restore normal tissue homeostasis or facilitate immune-mediated clearance (Source: Nature Reviews Drug Discovery, 2021).